What 18 Analyst Ratings Have To Say About Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:
|Last 30 Days||1 Month Ago||2 Months Ago||3 Months Ago|
In the last 3 months, 18 analysts have offered 12-month price targets for Biogen. The company has an average price target of $428.61 with a high of $647.00 and a low of $245.00.
This current average represents a 30.67% increase from the previous average price target of $328.0.
How Are Analyst Ratings Determined?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once per quarter.
Analysts can recommend “buy”, “sell”, “hold”, or similar verbage for each stock based on that company’s recent performance. “Buy” indicates that an analyst is optimistic about a stock’s short-term or mid-term growth and is a recommendation to purchase the stock. On the other hand, “Sell” implies that an analyst forecasts a downwards trend for the stock. “Hold” suggests that investors should maintain their positions on that stock because of forecasted stagnation or lack of new information.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.